valperinol
{{Short description|Chemical compound}}
{{Drugbox
| IUPAC_name = (1R,3R,4S,6R,7S,8R,10R)-8-methoxy-10-methyl-3-(1-piperidinylmethyl)-2,9-dioxatricyclo[4.3.1.03,7]decan-4-ol
| image = Valperinol.svg
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 64860-67-9
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 580OD29R6M
| ATC_prefix = None
| ATC_suffix =
| PubChem = 68849
| ChemSpiderID = 62082
| C = 16 | H = 27 | N = 1 | O = 4
| smiles = O1[C@@H](OC)[C@@H]2[C@@]3(O[C@H]1[C@@H]([C@H]2C[C@@H]3O)C)CN4CCCCC4
| StdInChI = 1S/C16H27NO4/c1-10-11-8-12(18)16(9-17-6-4-3-5-7-17)13(11)15(19-2)20-14(10)21-16/h10-15,18H,3-9H2,1-2H3/t10-,11-,12+,13-,14+,15-,16-/m1/s1
| StdInChIKey = KZSHXABWNBVUTK-GBIHRFPISA-N
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_category =
| legal_status = Non-regulated
| routes_of_administration =
}}
Valperinol (INN; GA 30-905) is a drug which acts as a calcium channel blocker.{{cite journal |vauthors=Thies PW, Asai A, Bán I, David S, Finner E | title = [The synthesis of valperinol and various 3-aminomethyl derivatives of 2,9-dioxatricyclo[4,3,1,0(3,7)]decane from didrovaltrate] | language = de | journal = Arzneimittel-Forschung | volume = 34 | issue = 11 | pages = 1460–3 | year = 1984 | pmid = 6543120 }}{{cite journal | author = Dose M | title = [Calcium antagonist properties of valperinol] | language = de | journal = Arzneimittel-Forschung | volume = 34 | issue = 11 | pages = 1464–6 | year = 1984 | pmid = 6098282 }} It was patented as a possible sedative, antiepileptic, and/or antiparkinsonian agent, but was never marketed.{{cite book | title = Dictionary of Pharmacological Agents Volume 2 | url = https://books.google.com/books?id=A0THacd46ZsC&pg=PA2104 | access-date = 22 April 2012 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 2104|date = 1996-11-21}}